BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743-745. [PMID: 22586011 DOI: 10.7326/0003-4819-156-10-201205150-00013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Yang S, Chen D. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. Journal of Microbiology, Immunology and Infection 2019;52:1-8. [DOI: 10.1016/j.jmii.2017.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
2 Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014;81:478-484. [PMID: 24561021 DOI: 10.1016/j.jbspin.2014.01.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
3 Cheung MC, Agarwal K. Liver abnormalities in the immunosuppressed. Best Practice & Research Clinical Gastroenterology 2013;27:597-618. [DOI: 10.1016/j.bpg.2013.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
5 Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33:164-75. [DOI: 10.1111/liv.12081] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
6 Yang JD, Girotra M, Restrepo A, Waheed S, Barlogie B, Duarte-rojo A. Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance. Annals of Hepatology 2014;13:461-5. [DOI: 10.1016/s1665-2681(19)30855-5] [Cited by in Crossref: 9] [Article Influence: 1.1] [Reference Citation Analysis]
7 Alhajeri H, Abutiban F, Al-Adsani W, Al-Awadhi A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkandari W, Dehrab A, Muhanna Ghanem AA, Hasan E, Hayat S, Saleh K, Tarakmeh H, Ali Y. Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. Rheumatol Int 2019;39:1483-97. [PMID: 31309293 DOI: 10.1007/s00296-019-04372-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cheung KS, Seto WK, Lai CL, Yuen MF. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int. 2016;10:407-414. [PMID: 26739135 DOI: 10.1007/s12072-015-9692-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
9 Loustaud-Ratti V, Jacques J, Debette-Gratien M, Carrier P. Hepatitis B and elders: An underestimated issue. Hepatol Res. 2016;46:22-28. [PMID: 25651806 DOI: 10.1111/hepr.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hockenbery DM, Strasser SI, Mcdonald GB. Gastrointestinal and Hepatic Complications. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. Chichester: John Wiley & Sons, Ltd; 2015. pp. 1140-60. [DOI: 10.1002/9781118416426.ch94] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Soriano V, Mcmahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Research 2013;100:435-8. [DOI: 10.1016/j.antiviral.2013.08.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
12 Xu Z, Dai W, Wu YT, Arshad B, Li X, Wu H, Chen HR, Wu KN, Kong LQ. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis. Eur J Cancer Care (Engl) 2018;27:e12799. [PMID: 29265535 DOI: 10.1111/ecc.12799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol 2014; 20(23): 7306-7311 [PMID: 24966601 DOI: 10.3748/wjg.v20.i23.7306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
14 Feuchtenberger M, Schäfer A, Philipp Nigg A, Rupert Kraus M. Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatol J 2016;10:39-48. [PMID: 27708728 DOI: 10.2174/1874312901610010039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sato K, Kobayashi T, Yamazaki Y, Takakusagi S, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C: HBV reactivation during DAA-based therapy. Hepatol Res 2017;47:1346-53. [DOI: 10.1111/hepr.12905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
16 McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54. [PMID: 24266913 DOI: 10.1016/j.mcna.2013.08.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
17 Harris AM, Millman AJ, Lora M, Osinubi A, Lom J, Miller LS. Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients. Vaccine 2019;37:2188-93. [PMID: 30902481 DOI: 10.1016/j.vaccine.2019.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016;164:30-40. [PMID: 26595058 DOI: 10.7326/M15-1121] [Cited by in Crossref: 92] [Cited by in F6Publishing: 37] [Article Influence: 13.1] [Reference Citation Analysis]
19 Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346-352. [PMID: 25220947 DOI: 10.1111/jvh.12305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
20 Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017;129:553-60. [PMID: 27903528 DOI: 10.1182/blood-2016-01-689422] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 16.8] [Reference Citation Analysis]
21 Marrone A, Capoluongo N, D'Amore C, Pisaturo M, Esposito M, Guastafierro S, Siniscalchi I, Macera M, Boemio A, Onorato L, Rinaldi L, Minichini C, Adinolfi LE, Sagnelli E, Mastrullo L, Coppola N. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2018;25:198-204. [PMID: 29029365 DOI: 10.1111/jvh.12802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
22 Ruan J, Li HJ, Sun DX. Reactivation of hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2014; 22(7): 927-932 [DOI: 10.11569/wcjd.v22.i7.927] [Reference Citation Analysis]
23 McMahon B, Block J, Block T, Cohen C, Evans AA, Hosangadi A, London WT, Sherman M; 2015 Princeton HCC Workshop participants. Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care. J Natl Cancer Inst 2016;108:djv359. [PMID: 26626106 DOI: 10.1093/jnci/djv359] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
24 Law MF, Lai HK, Chan HN, Ha CY, Ng C, Yeung YM, Yip SF. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma. Eur J Cancer Care (Engl). 2015;24:117-124. [PMID: 25848698 DOI: 10.1111/ecc.12166] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
25 Seo MR, Kim G, Moon KW, Sung YK, Yoo JJ, Yoon CH, Lee EB, Lee J, Kang EH, Kim H, Park EJ, Uhm WS, Lee MS, Lee SW, Choi BY, Hong SJ, Baek HJ. Quality Indicators for Evaluating the Health Care of Patients with Rheumatoid Arthritis: a Korean Expert Consensus. J Korean Med Sci 2021;36:e109. [PMID: 33942576 DOI: 10.3346/jkms.2021.36.e109] [Reference Citation Analysis]
26 Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol 2014; 20(43): 16037-16052 [PMID: 25473156 DOI: 10.3748/wjg.v20.i43.16037] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
27 Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018;70:724-731. [PMID: 28834412 DOI: 10.1002/acr.23346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
28 Abe M, Onji H, Koizumi Y, Hanayama M, Onji M, Hirooka M, Tokumoto Y. A Case of de novo Hepatitis B Complicated due to Lack of Comprehensive Interventional Approach. Euroasian Journal of Hepato-Gastroenterology 2012;2:122-5. [DOI: 10.5005/jp-journals-10018-1050] [Reference Citation Analysis]
29 Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep. 2013;15:319. [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
30 Yin XR, Zhong XZ, Liao HH, He JJ, Chen CH. Logistic regression analysis of factors influencing virological response to nucleos(t)ide analog therapy in previously untreated chronic hepatitis B patients. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 5039-5044 [DOI: 10.11569/wcjd.v23.i31.5039] [Reference Citation Analysis]
31 Lin TC, Hashemi N, Kim SC, Yang YK, Yoshida K, Tedeschi S, Desai R, Solomon DH. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken) 2018;70:30-8. [PMID: 28320050 DOI: 10.1002/acr.23241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
32 Hunt CM, Beste LA, Lowy E, Suzuki A, Moylan CA, Tillmann HL, Ioannou GN, Lim JK, Kelley MJ, Provenzale D. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. World J Gastroenterol 2016; 22(19): 4732-4740 [PMID: 27217704 DOI: 10.3748/wjg.v22.i19.4732] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
33 Calabrese LH, Calabrese C, Kirchner E. The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al. Arthritis Care Res (Hoboken) 2016;68:723-4. [PMID: 26866816 DOI: 10.1002/acr.22865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
34 Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;. [PMID: 33387124 DOI: 10.1007/s10620-020-06725-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am 2017;43:133-49. [PMID: 27890170 DOI: 10.1016/j.rdc.2016.09.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
36 Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.Hepatology. 2018;67:36-47. [PMID: 28653760 DOI: 10.1002/hep.29344] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 10.6] [Reference Citation Analysis]
37 Pompili M, Basso M, Hohaus S, Bosco G, Nosotti L, D’andrea M, Fenu S, Grieco A, Laurenti L, Mirisola C, Pagano L, Rapaccini GL, Sica S, Storti S, Landolfi R. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Annals of Hepatology 2015;14:168-74. [DOI: 10.1016/s1665-2681(19)30778-1] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
38 Niu JX, Xu Y, Wu DP. [Progress in the research of HBV reactivation in patients undergoing hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:348-52. [PMID: 33979984 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.016] [Reference Citation Analysis]
39 Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019; 25(26): 3299-3312 [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
40 Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. Liver Int. 2019;39:1292-1306. [PMID: 30983083 DOI: 10.1111/liv.14119] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
41 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 214] [Article Influence: 48.2] [Reference Citation Analysis]
42 Sanagawa A, Hotta Y, Kataoka T, Maeda Y, Kondo M, Kawade Y, Ogawa Y, Nishikawa R, Tohkin M, Kimura K. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Med 2018;7:2269-79. [PMID: 29663729 DOI: 10.1002/cam4.1429] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Patel A, Yapali S, Lok AS. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014. Hepatol Int 2016;10:139-46. [PMID: 26272106 DOI: 10.1007/s12072-015-9659-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Mortensen E, Kamali A, Schirmer PL, Lucero-Obusan C, Winston CA, Oda G, Winters MA, Durfee J, Martinello RA, Davey VJ, Holodniy M. Are current screening protocols for chronic hepatitis B virus infection adequate? Diagn Microbiol Infect Dis 2016;85:159-67. [PMID: 27009896 DOI: 10.1016/j.diagmicrobio.2015.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
45 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
46 Lombardi A, Mondelli MU. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Aliment Pharmacol Ther 2019;50:872-84. [PMID: 31378985 DOI: 10.1111/apt.15449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
47 Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81. [PMID: 26112647 DOI: 10.1016/j.antiviral.2015.06.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
48 Ramirez J, Duddempudi AT, Sana MM, Hasan SS, de Los Santos M, Song J, Fang-Hollingsworth Y, Gupta SS, Sears DM. Screening for hepatitis B in patients with lymphoma. Proc (Bayl Univ Med Cent) 2015;28:438-42. [PMID: 26424935 DOI: 10.1080/08998280.2015.11929300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Schmajuk G, Li J, Evans M, Anastasiou C, Izadi Z, Kay JL, Hammam N, Yazdany J. RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. Semin Arthritis Rheum 2020;50:1542-8. [PMID: 32234243 DOI: 10.1016/j.semarthrit.2020.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
51 Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703-711. [PMID: 25412906 DOI: 10.1002/hep.27609] [Cited by in Crossref: 134] [Cited by in F6Publishing: 115] [Article Influence: 19.1] [Reference Citation Analysis]
52 Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol 2015;87:1989-99. [PMID: 25989114 DOI: 10.1002/jmv.24270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]